Biomanufacturing Outsourcing Outlook - Industry optimism is on the rise for 2012. - BioPharm International

ADVERTISEMENT

Biomanufacturing Outsourcing Outlook
Industry optimism is on the rise for 2012.


BioPharm International
Volume 25, Issue 2, pp. 15-16

CONCLUSION

The bio/pharmaceutical industry is emerging from the current global economic situation into 2012 with a positive outlook. The industry is spending more, becoming more efficient, and, perhaps most importantly, expressing great optimism. With sales growth of between 14 and 18% this year, we will likely continue to see additional spending in new technology, capital equipment, and hiring.

Eric Langer is president of BioPlan Associates, tel. 301.921.5979,
, and a periodic contributor to Outsourcing Outlook.

REFERENCES

1. BioPlan Associates, 8th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production: A Survey of Biotherapeutic Developers and Contract Manufacturing Organizations (Rockville, MD), April 2011.

2. BioPlan Associates, Top 1000 Global Biopharmaceutical Facilities Index, http://www.top1000bio.com/index.asp, accessed June 20, 2011.

3. R.A Rader, Biopharmaceutical Products in the US and European Markets (database), BioPlan Associates, http://www.bioplanassociates.com/publications/pub_bpuseu.htm, accessed Jan. 16, 2012.

4. R. Rader, FDA Biopharmaceutical Product Approvals and Trends, Biotechnology Information Institute, http://www.biopharma.com/approvals_2011.html, accessed Jan. 16, 2012.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Launches Human Safety Study of Ebola Vaccine Candidate
August 29, 2014
Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
USP Awards Analytical Research
August 15, 2014
Author Guidelines
Source: BioPharm International,
Click here